GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunovant Inc (NAS:IMVT) » Definitions » Graham Number

Immunovant (Immunovant) Graham Number : $N/A (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Immunovant Graham Number?

Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.

As of today (2024-05-29), the stock price of Immunovant is $29.57. Immunovant's graham number for the quarter that ended in Dec. 2023 was $N/A. Therefore, Immunovant's Price to Graham Number ratio for today is N/A.

The historical rank and industry rank for Immunovant's Graham Number or its related term are showing as below:

IMVT's Price-to-Graham-Number is not ranked *
in the Biotechnology industry.
Industry Median: 2.08
* Ranked among companies with meaningful Price-to-Graham-Number only.

Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.


Immunovant Graham Number Historical Data

The historical data trend for Immunovant's Graham Number can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunovant Graham Number Chart

Immunovant Annual Data
Trend Dec18 Mar20 Mar21 Mar22 Mar23
Graham Number
- - - - -

Immunovant Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Graham Number Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Immunovant's Graham Number

For the Biotechnology subindustry, Immunovant's Price-to-Graham-Number, along with its competitors' market caps and Price-to-Graham-Number data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immunovant's Price-to-Graham-Number Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunovant's Price-to-Graham-Number distribution charts can be found below:

* The bar in red indicates where Immunovant's Price-to-Graham-Number falls into.



Immunovant Graham Number Calculation

Graham Number is a concept based on Ben Graham's conservative valuation of companies.

Immunovant's Graham Number for the fiscal year that ended in Mar. 2023 is calculated as

Graham Number
=sqrt of (22.5* Tangible Book per Share *EPS without NRI)
=sqrt of (22.5*2.781*-1.629)
=N/A

Immunovant's Graham Number for the quarter that ended in Dec. 2023 is calculated as

Graham Number
=sqrt of (22.5*Tangible Book per Share*EPS without NRI (TTM))
=sqrt of (22.5*4.682*-1.744)
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Immunovant  (NAS:IMVT) Graham Number Explanation

Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:

Current price should not be more than 15 times average earnings of the past three years.

Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)

Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.

In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.

Immunovant's Price to Graham number Ratio for today is calculated as

Price to Graham number=Share Price (Today)/Graham number (Q: Dec. 2023 )
=29.57/N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Please keep these in mind:

1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.


Immunovant Graham Number Related Terms

Thank you for viewing the detailed overview of Immunovant's Graham Number provided by GuruFocus.com. Please click on the following links to see related term pages.


Immunovant (Immunovant) Business Description

Traded in Other Exchanges
N/A
Address
320 West 37th Street, 6th Floor, New York, NY, USA, 10018
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).
Executives
William L. Macias officer: Chief Medical Officer C/O IMMUNOVANT, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
Eva Renee Barnett officer: Chief Financial Officer C/O IMMUNOVANT, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
Julia G. Butchko officer: Chief Dev. & Tech. Officer 320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Peter Salzmann director, officer: Chief Executive Officer 320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Atul Pande director C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018
Andrew J. Fromkin director C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FL, CAMBRIDGE MA 02139
George V Migausky director C/O DYAX CORP., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Mark S. Levine officer: Chief Legal Officer 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
Roivant Sciences Ltd. 10 percent owner CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Jay S Stout officer: Chief Technology Officer C/O VERSARTIS, INC., 4200 BOHANNON DR., SUITE 250, MENLO PARK CA 94025
Frank Torti director 2855 SAND HILL ROAD, MENLO PARK CA 94025
Douglas J. Hughes director C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134
Rita Jain officer: Chief Medical Officer C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Michael James Elliott officer: Chief Scientific Officer 320 WEST 37TH STREET, NEW YORK NY 10018
Eric Venker director C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018